Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$88.09 USD

88.09
281,676

-0.40 (-0.45%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $88.18 +0.09 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Reata (RETA) Soars on Potential Omaveloxolone NDA Filing

The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.

Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update

Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

Ekta Bagri headshot

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.

Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year

Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.

BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why

BioNTech (BNTX) is riding high on the robust performance of its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.

Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year

Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis

Benjamin Rains headshot

Find 'Strong Buy' Stocks Near Highs Amid Volatility

Given this backdrop, investors might want to consider buying stocks that have remained near their highs amid the volatility...

Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon

Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.

Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC

Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.

Kinjel Shah headshot

4 Biotech Stocks That Have Already Doubled This Year So Far

Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.

Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod

The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.

Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC

Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line

Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.

Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus

Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.

Company News for May 11, 2021

Companies in the news are: BNTX, WB, ES, J

The Zacks Analyst Blog Highlights: BioNTech, Western Digital and Orient Overseas International

The Zacks Analyst Blog Highlights: BioNTech, Western Digital and Orient Overseas International

John Blank headshot

3 Fast-Moving Stocks: Global Week Ahead

Most central banks are not yet unwinding money-printing or raising rates, but money supply growth has shrunk. And just how transitory will inflation be?

Stock Market News for May 7, 2021

Wall Street closed sharply higher on Thursday following strong labor market Data.

Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss

Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.

Panasonic (PCRFY) to Post FY2021 Earnings: What's in Store?

Despite accretive collaborations and profitability enhancement endeavors, Panasonic's (PCRFY) fiscal-year 2021 earnings are likely to have been hurt by lower revenues, fueled by COVID-19 adversities.

Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?

BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales

Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.

Q1 Earnings Season Maintains its Momentum

Q1 Earnings Season Maintains its Momentum.

Mark Vickery headshot

Pfizer, UnderArmour Beat; Trade Deficit at All-Time Low

A sense of caution has begun to permeate the market off near-all-time highs in the indexes, and Pfizer looks to be a recipient of this today.

BioNTech SE Sponsored ADR (BNTX) Stock Jumps 11%: Will It Continue to Soar?

BioNTech SE Sponsored ADR (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.